DrugBiological
Ublituximab clinical trials
Also written TG-1101, BRIUMVI and TG-20.
- studies test it
- 36
- open now
- 10
- in phase 3
- 9
- first study started
- 2008
Keep track of what changes. Save the ublituximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
36 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 11
- Phase 2
- 18
- Phase 3
- 9
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 13
TG Therapeutics, Inc. (22) · City of Hope Medical Center (2) · Johns Hopkins University (2) · Jennifer R. Brown, MD, PhD (1) · Laboratoire français de Fractionnement et de Biotechnologies (1) · Jonathan Santoro (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Maryland, Baltimore (1)
Often tested with
Tested in the same studies.
Umbralisib (12) · Acalabrutinib (2) · Ibrutinib (2) · Bendamustine (2) · Lenalidomide (2) · Fingolimod (1) · Tazemetostat (1)
Studies
Open first, then newest update. How each study uses ublituximab is read from its arms, and is right about nine times in ten.
Testing it · 36
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabRecruitingPhase 3TG Therapeutics, Inc.NCT05877963Written as Ublituximab
- An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression DisorderNot yet recruitingPhase 2Jonathan SantoroNCT07812181Written as Ublituximab
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruitingPhase 2TG Therapeutics, Inc.NCT07680946Written as Ublituximab
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)RecruitingPhase 2TG Therapeutics, Inc.NCT07673744Written as Ublituximab
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingPhase 2/3TG Therapeutics, Inc.NCT07220252Written as Ublituximab
- Ublituximab in Autoantibody Positive Immune Mediated Necrotizing MyopathyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07103746Written as Ublituximab
- Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisRecruitingNot applicableUniversity of Maryland, BaltimoreNCT06864936Written as Ublituximab
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisRecruitingPhase 4Johns Hopkins UniversityNCT07389590Written as Ublituximab
- Ublituximab (Briumvi) for Early Forms of Relapsing Multiple SclerosisRecruitingPhase 4Northwestern UniversityNCT07225361Written as Ublituximab
- Effects of Ublituximab on Motor Functions in Multiple SclerosisRecruitingEarly Phase 1Georgia State UniversityNCT06629428Written as Ublituximab
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3TG Therapeutics, Inc.NCT07211633Written as Ublituximab
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT04783415Written as Ublituximab
- An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisActive, not recruitingPhase 3TG Therapeutics, Inc.NCT04130997Written as Ublituximab
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingPhase 2Jennifer R. Brown, MD, PhDNCT04624633Written as Ublituximab
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedPhase 3TG Therapeutics, Inc.NCT02612311Written as Ublituximab
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedPhase 1TG Therapeutics, Inc.NCT04806035Written as Ublituximab
- Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedPhase 1/2University of Alabama at BirminghamNCT04692155Written as Ublituximab
- Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedPhase 2TG Therapeutics, Inc.NCT03828448Written as Ublituximab
- A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedPhase 2TG Therapeutics, Inc.NCT02656303Written as Ublituximab
- Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedPhase 2Weill Medical College of Cornell UniversityNCT04149821Written as Ublituximab
See all 36 studies that test ublituximab →
Given in every arm · 7 — ublituximab is usual care beside what is tested
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)RecruitingPhase 2TG Therapeutics, Inc.NCT07503873Written as Ublituximab
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedPhase 1TG Therapeutics, Inc.NCT03671590Written as Ublituximab
- Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedPhase 2/3TG Therapeutics, Inc.NCT03801525Written as Ublituximab
- Study of TG-1801 in Subjects With B-Cell LymphomaCompletedPhase 1TG Therapeutics, Inc.NCT03804996Written as Ublituximab
- Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone LymphomaCompletedPhase 2University of Colorado, DenverNCT04508647Written as Ublituximab
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedPhase 2TG Therapeutics, Inc.NCT04016805Written as Ublituximab
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedPhase 1/2TG Therapeutics, Inc.NCT03379051Written as Ublituximab
Codes
What other systems call ublituximab · ClinicalTrials.gg INT000673
- MeSH (NLM) C000619007ublituximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U59UGK3IPCUBLITUXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7876570ublituximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91078UblituximabOne source FDA
- DrugBank DB11850One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619007 | ublituximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U59UGK3IPC | UBLITUXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7876570 | ublituximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91078 | Ublituximab | One source FDA |
| DrugBank | DB11850 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.